Director, Clinical Development

Malcolm A. Finkelman, PhD

Associates of Cape Cod, Inc.

(1→3)-ß-D-Glucan: Pharmaceutical Contaminant and Biological Response Modifier
Friday, July 29, 2016
The establishment of consistent safety and efficacy of parenteral pharmaceutical products is a key goal in GMP operations. Within the spectrum of activities that support GMP operations, the control of bioactive ... read more